463336-07-4

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-(4-fluorophenyl)pyridine is used as an intermediate compound for the synthesis of various pharmaceutical drugs. Its unique structure allows it to be a key component in the development of new medications, particularly those targeting specific biological pathways or receptors.
Used in Chemical Research:
5-Bromo-2-(4-fluorophenyl)pyridine is used as a research compound in academic and industrial laboratories. Its properties and reactivity make it a valuable tool for studying chemical reactions, mechanisms, and the development of new synthetic methods.
Used in Material Science:
5-Bromo-2-(4-fluorophenyl)pyridine is used as a building block in the synthesis of advanced materials, such as organic semiconductors or functional polymers. Its incorporation into these materials can lead to improved properties, such as enhanced conductivity or specific binding capabilities.
Used in Agrochemical Industry:
5-Bromo-2-(4-fluorophenyl)pyridine is used as a precursor in the development of agrochemicals, such as pesticides or herbicides. Its chemical structure can be tailored to target specific pests or weeds, leading to more effective and selective control agents.
Used in Dye and Pigment Industry:
5-Bromo-2-(4-fluorophenyl)pyridine is used as a starting material for the synthesis of dyes and pigments. Its aromatic and halogenated nature can contribute to the color properties and stability of the final products, making it suitable for various applications, such as textiles, plastics, or inks.

InChI:InChI=1/C11H7BrFN/c12-9-3-6-11(14-7-9)8-1-4-10(13)5-2-8/h1-7H

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 1765-93-1 4-fluoroboronic acid 
• 437-29-6 tris(4-fluorophenyl)bismuthane 
• 223463-13-6 2-iodo-5-bromopyridine 

Downstream Products

• 1037829-64-3 3-[6-(4-fluoro-phenyl)-pyridin-3-yl]-acrylic acid ethyl ester 
• 1333171-10-0 (6S)-6-({3-[6-(4-fluorophenyl)-3-pyridinyl]-2-propynyl}oxy)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 58861-53-3 4-fluorophenylpyridine 

Relevant academic research and scientific papers

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Triarylbismuthanes as threefold aryl-transfer reagents in regioselective cross-coupling reactions with bromopyridines and quinolines

Cross-coupling studies using bromopyridines and bromoquinolines with triarylbismuths as threefold coupling reagents in substoichiometric amounts under Pd-catalysed conditions are disclosed. The reactivity was high with both mono- and dibromopyridyl substrates, and mono- and bis-couplings were carried out regioselectively. A library of monoaryl and diaryl pyridines was formed in high yields. A one-pot strategy provided a simple and straightforward synthesis of both symmetrical and unsymmetrical diarylpyridines. Arylations of 2-bromo- and 3-bromoquinolines were achieved with triarylbismuth reagents. This study demonstrates that triarylbismuths may be used as threefold arylating reagents for the synthesis of aryl pyridines and quinolines through couplings with bromopyridines and bromoquinolines under Pd-catalysed conditions. Copyright

Palladium-catalyzed highly regioselective 2-arylation of 2,x-dibromopyridines and its application in the efficient synthesis of a 17β-HSD1 inhibitor

2,3- and 2,5-Dibromopyridines reacted with arylboronic acids, catalyzed by Pd(OAc)2/PPh3 in the presence of K2CO 3 in CH3CN/MeOH (2:1) at 50 C for 24 h, to afford 2-arylpyridines in good to high yield

Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)

New analogues of antitubercular drug PA-824 were synthesized, featuring alternative side chain ether linkers of varying size and flexibility, seeking drug candidates with enhanced metabolic stability and high efficacy. Both α-methyl substitution and removal of the benzylic methylene were broadly tolerated in vitro, with a biaryl example of the latter class exhibiting an 8-fold better efficacy than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection and negligible fragmentation to an alcohol metabolite in liver microsomes. Extended linkers (notably propenyloxy, propynyloxy, and pentynyloxy) provided greater potencies against replicating M. tb (monoaryl analogues), with propynyl ethers being most effective under anaerobic (nonreplicating) conditions (mono/biaryl analogues). For benzyloxybenzyl and biaryl derivatives, aerobic activity was maximal with the original (OCH2) linker. One propynyloxy-linked compound displayed an 89-fold higher efficacy than the parent drug in the acute model, and it was slightly superior to antitubercular drug OPC-67683 in a chronic infection model.

Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals

The present invention relates to heteroarylcyclopropanecarboxamides of the formula I, in which Het, X, Ra, Rb, Rc, Rd, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.